Latest Breaking News On - அமனிதா மஸ்கரியா - Page 9 : comparemela.com
Meilenstein im Milliardenmarkt: Psyched Wellness beginnt präklinische Studie! Einzigartiges Businessmodell ohne große Konkurrenz!
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
Meilenstein im Milliardenmarkt: ANSCHNALLEN! Psyched Wellness beginnt präklinische Studie! Einzigartiges Businessmodell ohne große Konkurrenz!
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
Psyched Wellness Ltd.: Psyched Wellness Has Commenced Research on Muscimol for Various Ailments
Psyched Wellness Ltd. (
Company or
Psyched ) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that it has commenced research on Muscimol for various ailments, with a focus on mental health issues.
The research is led by Psyched Wellness s board member, Prof. David Nutt. Prof. Nutt is a psychiatrist at the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept. of Medicine, Hammersmith Hospital, Imperial College London and is the Chair of the Scientific Advisory Board for COMPASS Pathways.
Šamaanivana: jõulupühade šamanistlikud juured
telegram.ee - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from telegram.ee Daily Mail and Mail on Sunday newspapers.
Psyched Wellness Ltd.: Psyched Wellness Commences Pre-Clinical Trials of Amanita Muscaria Psyched Wellness Ltd. (formerly Duncan Park Holdings Corporation) (
CSE: PSYC) (OTCQB: DCNPF) (FSE: 5U9) (the
Company or
Psyched ) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to share that it has shipped its first batch of Amanita Muscaria extract to its CRO partner to commence the Pre-Clinical trials.
The Company sent 108 grams of highly concentrated Amanita Muscaria extract to its CRO s lab to begin the first phase of its Pre-Clinical Trial. This first batch of Amanita extract will be used in a study to determine the Maximum Tolerated Dose (MTD). The goal of the study is to determine the highest dose of our extract that will not cause unacceptable side effects or an overt toxicity in a defined period. This is a key first step in determining the appropriate dosage for our future products.